Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ERYC 125

ERYTHROMYCIN

Standard Dose
125MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview ERYC 125 is listed in Drugs@FDA under application 062648 (ANDA).

Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 125MG Sponsor PARKE DAVIS Submission history See approval history documents.

Structured Monograph

Clinical summary

Approval overview ERYC 125 is listed in Drugs@FDA under application 062648 (ANDA). Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 125MG Sponsor PARKE DAVIS Submission history See approval history documents.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.